May 14, 2024

Clue Genetics Inc. awarded SBIR Phase I grant from NSF

Clue Genetics Inc. today announced that it has been awarded a $275,000 Small Business Innovation Research (SBIR) Phase I grant from America’s Seed Fund, offered by the National Science Foundation (NSF). The funds will be used to build-out Clue’s metabologenomics technology platform for the delivery of products based on biomolecules derived from fungi. [EIN Presswire]

February 7, 2024

Clue Genetics and 5Metis Enter Collaboration

Clue Genetics Inc. and 5Metis, Inc. today announced that they have entered into a license and collaboration agreement focused on the discovery and development of novel biologically derived products for the crop protection sector. [EIN Presswire]

September 20, 2022

Clue Genetics appoints Ryan Busch to its advisory board

Clue Genetics Inc. has announced the appointment of Mr. Ryan Busch to its advisory board. Ryan is a seasoned business executive with 30 years of experience, having worked across sectors in both large and small companies. He has a finance and operations background and previously held senior positions at Mellon Ventures, Eaton Corporation and Koch Industries. Ryan has extensive experience in fund raising and deal execution and will assist the Clue Genetics Board and leadership team in securing future rounds of capital investment. [EIN Presswire]

July 28, 2022

Clue Genetics’ President and SAB members win the Ōmura Award from the Journal of Antibiotics

Clue Genetics Inc. is pleased to announce that a publication co-authored by the firm’s President, Dr Cedric Pearce and two of its scientific advisory board members, Professor Nicholas Oberlies and Dr. Huzefa Raja, both of the University of North Carolina at Greensboro, has been awarded this year’s prestigious Ōmura prize from the Journal of Antibiotics for an excellent research article. [EIN Presswire]

June 24, 2022

Clue appoints Dr. Peter P. Repetti as VP of Research

Clue Genetics Inc. is pleased to announce the appointment of Dr. Peter P. Repetti as its Vice President of Research. He will oversee development of Clue’s foundational platform of intellectual property centered on fungal genomes and will lead the company’s research initiatives in metabologenomics. [Business Wire]

May 6, 2022

Clue acquires large collection of rare fungi

Clue Genetics, Inc. today announced its acquisition of certain R&D assets of Mycosynthetix Inc., including a proprietary collection of living fungi. This unique resource will provide a foundation for the firm’s efforts to develop new drugs and valuable natural products. [Business Wire]

April 10, 2022

Clue announces second tranche of equity investment

Clue Genetics, Inc today reported that it has secured a second round of equity investment of Cassandra Holdings, Pte. Ltd., which was predicated on the company having reached certain research targets. The funds will be used to expand the firm’s proprietary genome database and advance its first product leads.

August 15, 2021

Clue successfully reaches initial R&D milestones

Clue Genetics, Inc., has announced the successful completion of its initial research milestones. The firm has now established its R&D platform infrastructure for housing and mining its proprietary database of fungal genomes. The team is now ready to scale-up work to sequence and analyze 10s of 1000s of genomes to identify new drug candidates as well as valuable molecules and enzymes for a range of different sectors.

November 1, 2019

Clue announces first tranche of start-up equity investment

Clue Genetics, Inc., a start-up focused on fungal genomics, today announced that it has raised an initial “Angel” equity investment from Cassandra Holdings Pte. Ltd., a Singapore-based private investment fund with a focus on the health, nutrition, and fitness sectors. The capital will be used to establish Clue’s initial IP infrastructure and demonstrate proof of principle for its R&D thesis.

For more information: